The debate on the prescription status of pseudoephedrine in the state of Kentucky heated up last week as the deputy director of the White House Office of National Drug Control Policy Benjamin Tucker on Wednesday told Kentucky lawmakers that they should mandate PSE to Rx-only status, according to reports.